Episode Details

Most people treat scars like an aesthetic afterthought, but hypertrophic scars and keloids are biologically active tissue: itchy, painful, stiff, inflamed, and often stubbornly persistent. In this Energy Code Deep Dive, Dr. Mike Belkowski breaks down a randomized double-blind clinical trial using a synergistic 3-part approach: microneedling + photodynamic therapy + methylene blue as the photosensitizer.

We walk through the exact protocol (5 weekly sessions), how results were measured (JSS + POSAS), and what actually improved — thickness, stiffness, pain, itching, flexibility, pigmentation, vascularity, and patient satisfaction. We also discuss why controlled ROS under photodynamic therapy is different from chronic oxidative stress, why keloids may respond better to 1% methylene blue, and what “resetting the remodeling environment” really means.

(Educational content only, not medical advice.)

-

Article Discussed in Episode:

Redefining scar quality: A synergistic approach with micro-needling and photodynamic therapy using methylene blue as a photosensitizer: a randomized clinical trial

-

Key Quotes From Dr. Mike:

“Scars aren’t just leftover tissue... they’re often biologically active.”

“Microneedling opens the pathway. Light delivers the signal. Methylene blue is the photochemical tool.”

“ROS (reactive oxygen species) isn’t ‘bad’— chronic ROS is bad. Controlled ROS can be therapeutic.”

“If you want to change tissue outcomes, you often have to change the tissue environment.”

“Methylene blue isn’t just a ‘mitochondria molecule'. In the right context, it’s a precision photochemical lever.”

-

Key points

•  

• Scars are biology, not just cosmetics; keloids/hypertrophic scars can stay inflamed and symptomatic.

• Trial design: randomized double-blind; 37 patients / 94 scars; 5 sessions, weekly.

• 4 groups: keloid vs hypertrophic × 0.1% vs 1% methylene blue.

• Protocol: microneedling (≈1–3 mm) → apply MB → occlude 30 min → light 15 min.

• Measured with JSS + POSAS (clinician + patient symptoms).

• Severity drop: JSS score fell roughly 14.69 → 4.69 by 6 months.

• POSAS: ~50% improvement after treatment; stable through 6 months.

• Biggest symptom wins: stiffness ↓ ~71%, itching ↓ ~70%, pain ↓ ~69%.

• 1% MB tended to outperform 0.1% for keloids (stronger photosensitizing effect/penetration).

• Low adverse events; keloid recurrence ~2% at 6 months; none reported for hypertrophic scars in that window.

• Mechanism logic: microneedling “restarts remodeling” + MB-PDT generates targeted ROS to modulate fibroblasts/collagen/inflammation.

• Limitations: small sample, no untreated control, subjective scales, limited objective imaging, follow-up only 6 months.

-

Episode timeline

• 0:19–1:31 Why scars are biology + the 3-part stack (microneedling + PDT + methylene blue)

• 1:36–2:17 Hypertrophic vs keloid + why standard care struggles (recurrence/side effects)

• 2:20–4:25 Trial setup: 37 patients / 94 scars, 4 groups, 5 weekly sessions + parameters

• 4:25–5:03 Outcomes measured: JSS + POSAS (clinician + patient symptoms)